(Q36445558)

14 August 2017

1 reference

title

Immunization strategies for the control of serogroup C meningococcal disease in developed countries (English)

1 reference

14 August 2017

0 references

meningococcal disease

1 reference

Philippe De Wals

1

1 reference

14 August 2017

publication date

1 April 2006

1 reference

Expert Review of Vaccines

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

269-275

1 reference

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Meningococcal polysaccharide-protein conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Serogroup C meningococcal outbreaks in the United States. An emerging threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Human immunity to the meningococcus. II. Development of natural immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Thymus-independent and thymus-dependent responses to polysaccharide antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vac

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Development of natural immunity to Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Meningococcal surrogates of protection--serum bactericidal antibody activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Invasive meningococcal and pneumococcal disease in Switzerland: cost?utility analysis of different vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.269

21 January 2018

Identifiers

DOI

10.1586/14760584.5.2.269

1 reference

14 August 2017

1 reference